Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
Returns
Return on equity-67.9%-56.5%-48%
Return on assets-58.6%-49.3%-7.7pp-42.3%-61.3%
Return on invested capital-80.5%-70.6%-62.7%
Liquidity
Current ratio8.2×-5.8×8.6×-6.8×11.6×+0.3×13.8×+9.2×13.9×
Quick ratio8.2×-5.8×8.6×-6.8×11.6×+0.3×13.8×+9.2×13.9×
Cash ratio-0.6×2.1×-1.2×2.3×-1.9×2.7×-0.5×2.5×
Leverage
Debt-to-equity0.1×0.0×0.1×0.0×0.1×0.0×0.1×0.1×
Debt-to-assets0.1×0.0×0.1×0.0×0.1×0.0×0.1×-0.1×0.1×
Per Share
Book value per share$3.56-48.7%$4.50-72.9%$5.28-50.4%$6.11+103%$6.93+103%
Valuation
Market capitalization$429.03M+1,015%$105.3M-57.0%$70.1M$39.22M$73.09M
Enterprise value$417.88M+1,832%$89.08M-59.3%$55.82M$23.52M$56.22M
Price / book4.9×+4.7×-0.4×0.5×0.3×0.4×
Free cash flow yield-18.7%+140pp-75.3%-52.6pp-112.6%-180.5%-83.4%
Earnings yield-20.3%+166pp-79.6%-52.9pp-113%-191.5%-98.1%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Artiva Biotherapeutics, Inc.'s ratios come from?
Every ratio is computed from Artiva Biotherapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.